[144] Kiniksa Pharmaceuticals International, plc SEC Filing

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 144 notifying a proposed sale of 85,271 Class A ordinary shares through Charles Schwab & Co., Inc. with an aggregate market value of $3,028,740, approximately to be sold on 09/04/2025 on NASDAQ. The shares were acquired the same day via an employee stock option exercise and were settled by a broker payment for a cashless exercise.

The filing also lists insider sales over the past three months by Eben Tessari totaling 381,932 shares across multiple dates with combined gross proceeds of $7,482,197.

Positive

• Full disclosure: The filing includes acquisition date, nature of acquisition, payment method, broker name, and proposed sale date as required.
• Relatively small proportion: The proposed sale of 85,271 shares represents a small fraction of the reported 43,472,928 shares outstanding, limiting immediate market impact.

Negative

• Insider sell pattern: Recent sales total 381,932 shares with gross proceeds of $7,482,197, which may be viewed by some investors as ongoing insider liquidation.
• Concentration of sales by one insider: All recent disclosed sales were by Eben Tessari, which could prompt investor questions about insider diversification or liquidity needs.

Insights

Securities Analyst

TL;DR: Insider proposes to sell newly exercised shares; recent substantial insider dispositions are disclosed but reflect exercised/options liquidity rather than company operations.

This Form 144 shows a current proposed sale of 85,271 shares following a same-day exercise and cashless settlement, which is a routine mechanism for option holders to monetize position without additional cash outlay. The historical sales by the same insider total 381,932 shares with gross proceeds of $7,482,197, indicating ongoing liquidation activity. From a market-impact perspective, the single proposed block represents less than 0.2% of the stated 43,472,928 shares outstanding, limiting potential dilution or market pressure from this filing alone.

Corporate Governance Expert

TL;DR: Disclosure is compliant and includes required attestations; the pattern of sales is documented but no governance red flags are evident from this notice alone.

The filer certified no undisclosed material adverse information and provided acquisition and payment details, including that the shares resulted from an employee stock option exercise and were cashless-exercised via a broker. The filing meets procedural requirements for Form 144. Investors seeking governance implications should combine this record with broader insider-trading patterns and company disclosures, as this single filing shows ordinary executive/insider liquidity rather than a governance event.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	85271	3028740.00	43472928	09/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	09/04/2025	Employee Stock Option Exercise	Kiniksa Pharmaceuticals International, plc			85271	09/04/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	06/09/2025	10319	313453.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	06/10/2025	15506	472239.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	06/11/2025	45042	1374277.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	06/16/2025	17300	489171.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	07/14/2025	18900	542860.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	08/05/2025	138614	4602409.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	08/18/2025	16200	547070.00
Eben Tessari 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	09/03/2025	15091	535778.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What exactly is being proposed for sale in the KNSA Form 144?

The filer proposes to sell 85,271 Class A ordinary shares through Charles Schwab & Co., Inc. with an aggregate market value of $3,028,740 on or about 09/04/2025 on NASDAQ.

How were the 85,271 KNSA shares acquired?

They were acquired on 09/04/2025 via an employee stock option exercise and settled by a broker payment for a cashless exercise on the same date.

Has the insider sold other KNSA shares recently?

Yes. Eben Tessari sold shares on multiple dates in June–September 2025 totaling 381,932 shares with combined gross proceeds of $7,482,197.

Does this Form 144 indicate any undisclosed material information about Kiniksa?

The filer represents by signature that they do not know any material adverse information not publicly disclosed; the filing itself contains no such undisclosed information.

Which broker is handling the proposed sale of KNSA shares?

The proposed sale is to be handled by Charles Schwab & Co., Inc. located at 3000 Schwab Way, Westlake, TX.